In phase 2 of their clinical trial testing the drug CTP-543 (a JAK 1 and JAK 2 inhibitor) as a treatment for Alopecia Areata, CoNCERT Pharmaceuticals has found that a statistically significant number of subjects have responded to the 8 mg and 12 mg oral dose of the drug given twice daily. A subject was considered responsive to the drug if they had greater or equal to a 50% reduction in their Severity of Alopecia Tool (SALT) score. Specifically, after 24 weeks of treatment, an absolute SALT score of less than or equal to 20 was achieved in 26% of subjects taking 8 mg twice daily, and 42% of subjects taking 12 mg twice daily. An absolute SALT score of less than or equal to 20 indicated that the subject had at least 80% clinically-meaningful scalp hair present.
Though there is still more work to be done, these results are very promising and we look forward to seeing how the trial progresses!
Link to full article: https://ir.concertpharma.com/news-releases/news-release-details/concert-pharmaceuticals-releases-additional-data-phase-2
